

## AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

### Listing of Claims:

1-47 (Cancelled)

48. (New) A method for treating a human patient suffering from stroke, said method comprising administering to said patient directly at the site of said stroke isolated human CD34+/-, Lin- cells from umbilical cord blood (UCB) or peripheral blood, wherein the administration of said cells results in measurable stroke recovery in said patient.

49. (New) The method of claim 48, wherein the cells are isolated from UCB.

50. (New) The method of claim 48, wherein the cells are isolated from peripheral blood.

51. (New) The method of claim 48 further comprising concurrently with or following administration of said cells administering a growth factor to said patient.

52. (New) The method of claim 51, wherein the growth factor is selected from the group consisting of oncostatin M, FGF, neurotrophin, IGF, CNTF, EGF, TGF-beta, LIF, interleukins, PDGF, and VEGF.

53. (New) The method of claim 48, wherein said cells are allogeneic cells.
54. (New) The method of claim 48, wherein said cells are autologous cells.
55. (New) The method of claim 48, wherein the cells are characterized as negative for expression of CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, and glycophorin A, and positive for expression of flk-1, CD45, CXCR4, and MDR.